News >

Optimizing HER2-Targeted Therapy

Gina Battaglia, PhD
Published: Monday, Mar 19, 2018

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD
The introduction of HER2-targeted therapies has drastically improved long-term survival for patients with HER2-positive breast cancer and provided numerous treatment options for all stages of the disease. “The good side to HER2-positive disease is the number of therapies we have available,” Sara Hurvitz, MD, director of the Breast Cancer Clinical Research Program at the University of California, Los Angeles (UCLA), and associate professor at the David Geffen School of Medicine at UCLA said in an interview with OncLive. “Women can live a long time with this disease.”


To Escalate or De-escalate Therapy?

Although targeted therapies are a mainstay of treatment, results from recent research show that management of HER2-positive breast cancer should not be a one-size-fits-all approach (Table). Identifying the low-risk patients who can receive standard-of-care treatment and the high-risk patients who should receive additional therapy is important to individualizing treatment and were the the central theme of Verma's talk, “Individualizing Therapy for Early-Stage HER2+ Breast Cancer: To Escalate or De-escalate?" at the recent Miami Breast Cancer Conference® (MBCC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication